Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens

Published: Tuesday, August 27, 2013
Last Updated: Tuesday, August 27, 2013
Bookmark and Share
One shot of the vaccine will prevent babies from five diseases at once.

The Indonesian Ministry of Health will introduce a new immunization program, and a pentavalent vaccine for babies aged 2 months to 1 year.

One shot of the pentavalent vaccine will prevent babies from five diseases at once, including Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae Type B.

The pentavalent vaccine, produced by Bio Farma, has been in development since 2007. The product will be launched along with the new immunization program by the Ministry of Health on August 22nd, in Lapangan Karang Pawitan Kabupaten Karawang.

The combination of five antigens is possible due to the similar schedule for 2, 3 & 4 month old babies. With the pentavalent vaccine, babies will require only one shot which contains the five antigens.

Babies are currently given two shots in one period of time, the DTPHB and HIB vaccines. Some babies require three shots, DPT, Hepatitis B and HIB vaccines.

The Production Director of Bio Farma, Juliman, said besides lowering the frequency of babies' shots, the pentavalent vaccine leads to greater efficiencies. "The use of pentavalent vaccine is expected to diminish production costs, cold chain costs, injector costs, and encourage health officers to be efficient. This cost efficiency will translate to affordability for the people."

Juliman added that with the various advantages, the use of pentavalent vaccine is projected to become a future trend for vaccine producers in developing countries.

Juliman spoke during the Global Alliance for Vaccines and Immunization (GAVI), held at Bio Farma on August 21st.

Clinical Trial

Bio Farma has held clinical trials for the pentavalent vaccine since 2010. The vaccine has passed the phase III clinical trial process, ensuring its efficacy for humans.

The trial was conducted with Hasan Sadikin Hospital / Medical Faculty of Padjajaran University and Cipto Mangunkusumo Hospital / Medical Faculty of Indonesian University. Pentavalent has also been registered with the National Agency of Drug & Food Control (NADFC).

"This year we will produce and supply the vaccine to four provinces, West Java, Bali, NTB and Yogyakarta, while later we will be able to produce and fulfill the demand of all provinces of Indonesia," said Juliman.

He predicted that the pentavalent vaccine demand in Indonesia will reach 15 million doses a year, based on the average number of babies' births in Indonesia of 5 million per year.

Besides fulfilling domestic demand, Bio Farma plans to export the vaccine to the other countries after the vaccine passes the WHO prequalification assessment, a requirement for the vaccine to be accepted internationally.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!